Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

BACKGROUND: The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC. In addition, the immunologic impact of enza...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Madan, Ravi A, Karzai, Fatima, Donahue, Renee N, Al-Harthy, Munjid, Bilusic, Marijo, Rosner, Inger I, Singh, Harpreet, Arlen, Philip M, Theoret, Marc R, Marté, Jennifer L, Cordes, Lisa, Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Owens, Helen, Lochrin, Sarah E, Chau, Cindy H, Steinberg, Seth, Figg, William Douglas, Dahut, William, Schlom, Jeffrey, Gulley, James L
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934713/
https://ncbi.nlm.nih.gov/pubmed/33664086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001556
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares